Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastatic melanoma: Exploration of clinical and molecular predictors of response.

被引：0
|
作者：
McQuade, Jennifer Leigh
Chen, Guo
Panka, David J.
Reuben, Alexandre
Bassett, Roland L.
Joon, Aron
Lazar, Alexander J. F.
Tetzlaff, Michael T.
Simpson, Lauren
Mouton, Rosalind
Patel, Sapna Pradyuman
Glitza, Isabella Claudia
Hwu, Wen-Jen
Amaria, Rodabe Navroze
Diab, Adi
Hwu, Patrick
Wargo, Jennifer Ann
Sullivan, Ryan J.
Kim, Kevin
Davies, Michael A.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[4] UnMD Anderson Canc Ctr, Houston, TX USA
[5] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
[6] Calif Pacific Med Ctr, Res Inst, Oakland, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20051
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma A Phase 2 Clinical Trial
    Chen, Guo
    McQuade, Jennifer L.
    Panka, David J.
    Hudgens, Courtney W.
    Amin-Mansour, Ali
    Mu, Xinmeng Jasmine
    Bahl, Samira
    Jane-Valbuena, Judit
    Wani, Khalida M.
    Reuben, Alexandre
    Creasy, Caitlyn A.
    Jiang, Hong
    Cooper, Zachary A.
    Roszik, Jason
    Bassett, Roland L., Jr.
    Joon, Aron Y.
    Simpson, Lauren M.
    Mouton, Rosalind D.
    Glitza, Isabella C.
    Patel, Sapna P.
    Hwu, Wen-Jen
    Amaria, Rodabe N.
    Diab, Adi
    Hwu, Patrick
    Lazar, Alexander J.
    Wargo, Jennifer A.
    Garraway, Levi A.
    Tetzlaff, Michael T.
    Sullivan, Ryan J.
    Kim, Kevin B.
    Davies, Michael A.
    JAMA ONCOLOGY, 2016, 2 (08) : 1056 - 1064
  • [2] Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma
    Schadendorf, Dirk
    Amonkar, Mayur M.
    Stroyakovskiy, Daniil
    Levchenko, Evgeny
    Gogas, Helen
    de Braud, Filippo
    Grob, Jean-Jacques
    Bondarenko, Igor
    Garbe, Claus
    Lebbe, Celeste
    Larkin, James
    Chiarion-Sileni, Vanna
    Millward, Michael
    Arance, Ana
    Mandala, Mario
    Flaherty, Keith T.
    Nathan, Paul
    Ribas, Antoni
    Robert, Caroline
    Casey, Michelle
    DeMarini, Douglas J.
    Irani, Jhangir G.
    Aktan, Gursel
    Long, Georgina V.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (07) : 833 - 840
  • [3] Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+metastatic melanoma
    Latimer, Nicholas R.
    Amonkar, Mayur M.
    Stapelkamp, Ceilidh
    Sun, Peng
    MELANOMA RESEARCH, 2015, 25 (06) : 528 - 536
  • [4] Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
    Ascierto, Paolo A.
    Minor, David
    Ribas, Antoni
    Lebbe, Celeste
    O'Hagan, Anne
    Arya, Niki
    Guckert, Mary
    Schadendorf, Dirk
    Kefford, Richard F.
    Grob, Jean-Jacques
    Hamid, Omid
    Amaravadi, Ravi
    Simeone, Ester
    Wilhelm, Tabea
    Kim, Kevin B.
    Long, Georgina V.
    Martin, Anne-Marie
    Mazumdar, Jolly
    Goodman, Vicki L.
    Trefzer, Uwe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) : 3205 - +
  • [5] Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
    Long, G. V.
    Flaherty, K. T.
    Stroyakovskiy, D.
    Gogas, H.
    Levchenko, E.
    de Braud, F.
    Larkin, J.
    Garbe, C.
    Jouary, T.
    Hauschild, A.
    Chiarion-Sileni, V.
    Lebbe, C.
    Mandala, M.
    Millward, M.
    Arance, A.
    Bondarenko, I.
    Haanen, J. B. A. G.
    Hansson, J.
    Utikal, J.
    Ferraresi, V.
    Mohr, P.
    Probachai, V.
    Schadendorf, D.
    Nathan, P.
    Robert, C.
    Ribas, A.
    Davies, M. A.
    Lane, S. R.
    Legos, J. J.
    Mookerjee, B.
    Grob, J. -J.
    ANNALS OF ONCOLOGY, 2017, 28 (07) : 1631 - 1639
  • [6] A randomized phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma
    Straume, O.
    Schuster, C.
    Aziz, S.
    Davidsen, K.
    Karlsen, J.
    Rayford, A. J.
    Siraji, M. I.
    Svendsen, H. Lovendahl
    Reisaeter, L.
    Gjertsen, B. T.
    Akslen, L.
    Lorens, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1291 - S1291
  • [7] Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
    Kim, Kevin B.
    Kefford, Richard
    Pavlick, Anna C.
    Infante, Jeffrey R.
    Ribas, Antoni
    Sosman, Jeffrey A.
    Fecher, Leslie A.
    Millward, Michael
    McArthur, Grant A.
    Hwu, Patrick
    Gonzalez, Rene
    Ott, Patrick A.
    Long, Georgina V.
    Gardner, Olivia S.
    Ouellet, Daniele
    Xu, Yanmei
    DeMarini, Douglas J.
    Le, Ngocdiep T.
    Patel, Kiran
    Lewis, Karl D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04) : 482 - 489
  • [8] Adjusting for confounding effects of treatment crossover in a randomized phase 2 study of dabrafenib plus trametinib in BRAF V600+metastatic melanoma
    Latimer, Nicholas
    Amonkar, Mayur
    Stapelkamp, Ceilidh
    Sun, Peng
    CANCER RESEARCH, 2014, 74 (19)
  • [9] Clinical characteristics and survival of BRAF-mutant (BRAF plus ) metastatic melanoma patients (pts) treated with BRAF inhibitor (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD)
    Chan, Matthew
    Haydu, Lauren
    Menzies, Alexander M.
    Azer, Mary W. F.
    Klein, Oliver
    Guminski, Alexander
    Kefford, Richard
    Long, Georgina
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Updated overall survival (OS) results for BRF113220, a phase I-II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM)
    Daud, Adil
    Weber, Jeffrey S.
    Sosman, Jeffrey Alan
    Kim, Kevin
    Gonzalez, Rene
    Hamid, Omid
    Infante, Jeffrey R.
    Cebon, Jonathan S.
    Schuchter, Lynn Mara
    Long, Georgina V.
    Algazi, Alain Patrick
    Kudchadkar, Ragini Reiney
    Puzanov, Igor
    Lawrence, Donald P.
    Kefford, Richard
    Kline, Amy S.
    Del Buono, Heather Lynn
    Sun, Peng
    McDowell, Diane Opatt
    Flaherty, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345